» Articles » PMID: 23024702

Ultrastable Synergistic Tetravalent RNA Nanoparticles for Targeting to Cancers

Overview
Journal Nano Today
Specialty Biotechnology
Date 2012 Oct 2
PMID 23024702
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

One of the advantages of nanotechnology is the feasibility to construct therapeutic particles carrying multiple therapeutics with defined structure and stoichiometry. The field of RNA nanotechnology is emerging. However, controlled assembly of stable RNA nanoparticles with multiple functionalities which retain their original role is challenging due to refolding after fusion. Herein, we report the construction of thermodynamically stable X-shaped RNA nanoparticles to carry four therapeutic RNA motifs by self-assembly of reengineered small RNA fragments. We proved that each arm of the four helices in the X-motif can harbor one siRNA, ribozyme, or aptamer without affecting the folding of the central pRNA-X core, and each daughter RNA molecule within the nanoparticle folds into their respective authentic structures and retains their biological and structural function independently. Gene silencing effects were progressively enhanced as the number of the siRNA in each pRNA-X nanoparticles gradually increased from one to two, three, and four. More importantly, systemic injection of ligand-containing nanoparticles into the tail-vein of mice revealed that the RNA nanoparticles remained intact and strongly bound to cancers without entering the liver, lung or any other organs or tissues, while remaining in cancer tissue for more than 8 h.

Citing Articles

Inhibition of Endothelial Cell Tube Formation by Anti-Vascular Endothelial Growth Factor/Anti-Angiopoietin-2 RNA Nanoparticles.

Zhong C, Shi Z, Liu C, Binzel D, Jin K, Li X Pharmaceutics. 2025; 17(1).

PMID: 39861703 PMC: 11769471. DOI: 10.3390/pharmaceutics17010055.


Autonomous Nucleic Acid and Protein Nanocomputing Agents Engineered to Operate in Living Cells.

Panigaj M, Basu Roy T, Skelly E, Chandler M, Wang J, Ekambaram S ACS Nano. 2025; 19(2):1865-1883.

PMID: 39760461 PMC: 11757000. DOI: 10.1021/acsnano.4c13663.


Development of an RNA Nanostructure for Effective Control through Spray-Induced Gene Silencing without an Extra Nanocarrier.

Wu F, Yan L, Zhao X, Lv C, Jin W J Fungi (Basel). 2024; 10(7).

PMID: 39057368 PMC: 11277573. DOI: 10.3390/jof10070483.


Posterior eye delivery of angiogenesis-inhibiting RNA nanoparticles via subconjunctival injection.

Zhong C, Shi Z, Binzel D, Jin K, Li X, Guo P Int J Pharm. 2024; 657:124151.

PMID: 38657717 PMC: 11221552. DOI: 10.1016/j.ijpharm.2024.124151.


Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles.

Lin J, Wang X, Ni D, Chen Y, Chen C, Liu Y ACS Mater Au. 2023; 3(6):584-599.

PMID: 38089659 PMC: 10636764. DOI: 10.1021/acsmaterialsau.3c00035.


References
1.
Guha M, Plescia J, Leav I, Li J, Languino L, Altieri D . Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res. 2009; 69(12):4954-8. PMC: 2718425. DOI: 10.1158/0008-5472.CAN-09-0584. View

2.
Lyubchenko Y, Shlyakhtenko L . AFM for analysis of structure and dynamics of DNA and protein-DNA complexes. Methods. 2008; 47(3):206-13. PMC: 2667448. DOI: 10.1016/j.ymeth.2008.09.002. View

3.
Shu Y, Cinier M, Fox S, Ben-Johnathan N, Guo P . Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach. Mol Ther. 2011; 19(7):1304-11. PMC: 3129561. DOI: 10.1038/mt.2011.23. View

4.
Baugh C, Grate D, Wilson C . 2.8 A crystal structure of the malachite green aptamer. J Mol Biol. 2000; 301(1):117-28. DOI: 10.1006/jmbi.2000.3951. View

5.
Gold L . The SELEX process: a surprising source of therapeutic and diagnostic compounds. Harvey Lect. 1995; 91:47-57. View